BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. INZY (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2023, which is…Read More
Inozyme Pharma Announces Presentation at the American Society of Nephrology ASN Kidney Week 2023 Inozyme Pharma NASDAQINZY
